p16/Ki ‐67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow‐up

CONCLUSIONSA long‐term evaluation of p16/Ki‐67 dual labeling may identify HGUC and progression in cases with negative/low‐grade urinary cytology results, and there are potential implications for the clinical management of patients after the conservative treatment of non–muscle‐invasive urothelial carcinoma. Cancer Cytopathol 2017. © 2017 American Cancer Society.

Source: Cancer Cytopathology - April 3, 2017 Category: Pathology Authors: Eric Piaton, Anne ‐Sophie Advenier, Christian Carré, Myriam Decaussin‐Petrucci, Florence Mège‐Lechevallier, Karine Hutin, Cindy Nennig, Marc Colombel, Alain Ruffion Tags: Original Article Source Type: research